Client success details
To achieve this FutureBridge recommended the evaluation of evidence from preclinical, clinical, and patent levels. FutureBridge answered several key business questions :
- What are the targets/MoAs/modalities in all stages of innovation and development (early and clinical) that have shown promising efficacy/safety to transform SCCHN landscape?
- What are the targets/MoAs/modalities in clinics that are yet to demonstrate efficacy/safety, however, have shown early signals of activity in preclinical models and can emerge in the distant future?
- What is the availability of selected assets for partnership/in-licensing?
FutureBridge conducted extensive primary and secondary research to develop a concise view. These insights would be leveraged by the client to align their R&D efforts, take investment decisions, and formulate a long-term strategy to maintain a leadership position in SCCHN.